![Prognostic variables in node-negative and node-positive breast cancer [electronic resource] /](/search/themes/bootstrap3/images/libros.png)
Prognostic variables in node-negative and node-positive breast cancer [electronic resource] /
Prognostic variables in node-negative and node-positive breast cancer — Introduction -- Routinely available indicators of prognosis in breast cancer -- Prognostic factors for patients with breast cancers 1cm and smaller -- Steroid hormone receptors in breast cancer management -- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer -- S-phase fraction and breast cancer — a decade of experience -- Prognostic and predictive value of thymidine labelling index in breast cancer -- Cyclin D1 in breast cancer -- Cyclins and breast cancer -- Prognostic implications of expression of the cell cycle inhibitor p27Kip1 -- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer -- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients -- HER-2/neu as a predictive marker of response to breast cancer therapy -- Prognostic and predictive value of p53 and p21 in breast cancer -- The urokinase plasminogen activator system as a target for prognostic studies in breast cancer -- Metalloproteinases and tissue inhibitors of metalloproteinases -- Matrix metalloproteinase inhibitors -- The 67 kDa laminin receptor as a prognostic factor in human cancer -- Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis -- Clinical significance of angiogenic factors in breast cancer -- Insulin-like growth factors in human breast cancer -- Molecular prognostic markers in breast cancer -- Prognostic significance of micrometastatic bone marrow involvement -- Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis -- Time-dependence of hazard ratios for prognostic factors in primary breast cancer -- Circulating tumor markers in breast cancer: Accepted utilities and novel prospects -- The relationship between prognostic and predictive factors in the management of breast cancer -- Methodological challenges in the evaluation of prognostic factors in breast cancer -- Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? -- Prognostic variables in node-negative and node-positive breast cancer — editorial -- Author index.
| Main Authors: | , |
|---|---|
| Format: | Texto biblioteca |
| Language: | eng |
| Published: |
Boston, MA : Springer US : Imprint: Springer,
1998
|
| Subjects: | Medicine., Oncology., Medicine & Public Health., |
| Online Access: | http://dx.doi.org/10.1007/978-1-4615-5195-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Prognostic variables in node-negative and node-positive breast cancer — Introduction -- Routinely available indicators of prognosis in breast cancer -- Prognostic factors for patients with breast cancers 1cm and smaller -- Steroid hormone receptors in breast cancer management -- S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer -- S-phase fraction and breast cancer — a decade of experience -- Prognostic and predictive value of thymidine labelling index in breast cancer -- Cyclin D1 in breast cancer -- Cyclins and breast cancer -- Prognostic implications of expression of the cell cycle inhibitor p27Kip1 -- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer -- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients -- HER-2/neu as a predictive marker of response to breast cancer therapy -- Prognostic and predictive value of p53 and p21 in breast cancer -- The urokinase plasminogen activator system as a target for prognostic studies in breast cancer -- Metalloproteinases and tissue inhibitors of metalloproteinases -- Matrix metalloproteinase inhibitors -- The 67 kDa laminin receptor as a prognostic factor in human cancer -- Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis -- Clinical significance of angiogenic factors in breast cancer -- Insulin-like growth factors in human breast cancer -- Molecular prognostic markers in breast cancer -- Prognostic significance of micrometastatic bone marrow involvement -- Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis -- Time-dependence of hazard ratios for prognostic factors in primary breast cancer -- Circulating tumor markers in breast cancer: Accepted utilities and novel prospects -- The relationship between prognostic and predictive factors in the management of breast cancer -- Methodological challenges in the evaluation of prognostic factors in breast cancer -- Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful? -- Prognostic variables in node-negative and node-positive breast cancer — editorial -- Author index. |
|---|